Gaining momentum Lilly has gained sales momentum in head-to-head competition with Novo Nordisk to bring to market GLP-1 drugs for obesity and diabetesled by tirzepatide, marketed for adult type 2 diabetes as Mounjaro and for obesity as Zepbound
Semaglutide causes significant appetite suppression, which leads to reduced caloric intake, which can deplete NAD+ levels, which reduces cellular energy, which contributes to GLP-1 fatigue
What lifestyle changes should accompany Tirzepatide treatment for the best results
GLP-1-induced insulin synthesis is initiated by Pdx1
Tyrosinase is the enzyme responsible for producing melanin, the pigment that gives skin its color
Glutathione contains a high amount of cysteine, which is a sulfur-containing amino acid